Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Phase III Study for Evaluating the Role of the Addition of Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain in Premenopause or Regain Menstruation After Chemotherapy
Brief Summary: The purpose of this study is to compare 5-year disease free survival rate (DFS rate) between the hormone receptor positive breast cancer patients who were added Goserelin to Tamoxifen for ovarian function suppression after neo-/adjuvant cytotoxic chemotherapy and the hormone receptor positive breast cancer patients who were treated with Tamoxifen.


Options:
A: Arm Label: AZ (Arimidex+Zoledronate); Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole, Drug: zoledronic acid, Other: goserelin | Arm Label: TZ (Tamoxifen+Zoledronate); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: zoledronic acid, Other: goserelin | Arm Label: AC (Arimidex Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole, Other: goserelin | Arm Label: TC (Tamoxifen Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Other: goserelin | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): TC (Tamoxifen Control), TZ (Tamoxifen+Zoledronate) | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): AC (Arimidex Control), AZ (Arimidex+Zoledronate) | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): AZ (Arimidex+Zoledronate), TZ (Tamoxifen+Zoledronate) | Intervention Type: OTHER; Name: goserelin; Assigned to Arm(s): AC (Arimidex Control), AZ (Arimidex+Zoledronate), TC (Tamoxifen Control), TZ (Tamoxifen+Zoledronate)
B: Arm Label: Switch to Zoladex + AI for 3-2 years; Type: EXPERIMENTAL; Interventions: Drug: Zoladex+AI | Arm Label: TAM; Type: EXPERIMENTAL; Interventions: Drug: TAM | Intervention Type: DRUG; Name: Zoladex+AI; Assigned to Arm(s): Switch to Zoladex + AI for 3-2 years | Intervention Type: DRUG; Name: TAM; Assigned to Arm(s): TAM
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: TAM+OFS(E) group; Type: EXPERIMENTAL; Interventions: Drug: goserelin, Drug: tamoxifen | Arm Label: TAM(D) group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen | Arm Label: Permanent postmenopausal(A) group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TAM(B); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen | Arm Label: TAM+OFS (C); Type: EXPERIMENTAL; Interventions: Drug: goserelin, Drug: tamoxifen | Intervention Type: DRUG; Name: goserelin; Assigned to Arm(s): TAM+OFS (C), TAM+OFS(E) group | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): TAM(B), TAM(D) group, TAM+OFS (C), TAM+OFS(E) group

Answer: D